Key result
Prior COVID-19 in hypertensive patients is linked to worse atherogenic lipid and prothrombotic profiles.
Why the study?
An increase in frequency and severity of arterial hypertension after COVID-19 necessitates studying lipid metabolism and hemostasis changes in these patients.
Does a history of COVID-19 alter lipid metabolism and hemostasis in patients with arterial hypertension?
Observational (n=221)
Does a history of COVID-19 alter lipid metabolism and hemostasis in patients with arterial hypertension?
A history of COVID-19 in patients with arterial hypertension is associated with long-term atherogenic lipid changes and a prothrombotic state.
Should not yet change management in hypertensive patients with prior COVID-19; hypothesis-generating for persistent atherogenic and prothrombotic effects needing prospective validation.
An increase in the frequency of patients with arterial hypertension (AH) seeking medical care and its more severe course after a novel coronavirus infection (NCI), COVID-19, determines the need to study possible pathogenetic mechanisms of disease progression. Aim of the study was to investigate some features of lipid metabolism and changes in hemostasis in patients with AH after NCI COVID-19. Material and methods. An analysis of the most informative indicators of lipid metabolism and hemostasis was carried out in 104 patients with AH underwent (more than 2 months ago) NCI, in comparison with 117 patients with AH, with no history of COVID-19. The study included men and women aged from 30 to 75 years. Determination of the concentration of lipids in blood serum was carried out using the photometric method on a biochemical analyzer AU 480 (Beckman Coulter, США). Hemostatic parameters were determined by the chromogenic method using an automatic hemostasis analyzer Technology Solution 190 (USA). Results and discussion. It was found that patients with AH underwent NCI had significantly higher serum levels of total cholesterol, LDL cho- lesterol, triglycerides, D-dimers, platelets and lower activated partial thromboplastin and thrombin time compared with patients without COVID-19. Conclusions. The data obtained indicate a tendency to atherogenic changes in the blood lipid profile and increased coagulation processes in patients with AH in the long-term period (more than 2 months) after suffering a NCI COVID-19.
No takes yet. Share an insight, caveat, or question.
Sevostyanova et al. (2024) conducted an observational in Arterial hypertension (n=221). History of COVID-19 vs. No history of COVID-19 was evaluated on Serum levels of total cholesterol, LDL cholesterol, triglycerides, D-dimers, platelets, activated partial thromboplastin, and thrombin time. A history of COVID-19 in patients with arterial hypertension was associated with significantly higher atherogenic lipids, D-dimers, and platelets, and lower activated partial thromboplastin time.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: